Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 93-104 , January 2006

Positron Emission Tomography in Gynecologic Cancer

  • Tzu-Chen Yen, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Molecular Imaging Center, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
    • ,
  • Chyong-Huey Lai, MD

      Affiliations

    • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
    • Corresponding Author InformationAddress reprint requests to Chyong-Huey Lai, MD, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, 5 Fu-Shin St., Kueishan, Taoyuan 333, Taiwan.

References 

  1. Bos R , van Der Hoeven JJ , van Der Wall E , et al.   Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography . J Clin Oncol . 2002;20:379–387
  2. Kostakoglu L , Goldsmith SJ . 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma . J Nucl Med . 2003;44:224–239
  3. Higashi K , Ueda Y , Arisaka Y , et al.   18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer . J Nucl Med . 2002;43:39–45
  4. Torizuka T , Nakamura F , Kanno T , et al.   Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma . Eur J Nucl Med . 2004;31:22–28
  5. Kunkel M , Reichert TE , Benz P , et al.   Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma . Cancer . 2003;97:1015–1024
  6. Gerbaudo VH , Britz-Cunningham S , Sugarbaker DJ , et al.   Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma . Thorax . 2003;58:1077–1082
  7. Lerman H , Metser U , Grisaru D , et al.   Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients (assessment by PET/CT) . J Nucl Med . 2004;45:266–271
  8. Yen TC , Ng KK , Ma SY , et al.   Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer . J Clin Oncol . 2003;21:3651–3658
  9. Ma SY , See LC , Lai CH , et al.   Delayed [18F]-2-fluoro-2-deoxy-glucose positron emission tomography for detection of para-aortic lymph node metastases in cervical cancer patients . J Nucl Med . 2003;44:1775–1783
  10. Chao A, Chang YC, Hsueh S, et al: F-18 fluorodeoxyglucose positron emission tomography in the management of endometrial cancer. Eur J Nucl Med Mol Imaging (in press)
  11. Hacker NF . Cervical cancer . In:  Berek JS ,  Hacker NF editor. Practical Gynecologic Oncology . (ed 3). Pliladelphia: Lippincott Williams & Wilkins; 2000;p. 345–405
  12. Waggoner SE . Cervical cancer . Lancet . 2003;361:2217–2225
  13. Landoni F , Maneo A , Colombo A , et al.   Randomized study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer . Lancet . 1997;350:535–540
  14. Lai CH , Hong JH , Hsueh S , et al.   Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases . Cancer . 1999;85:1537–1546
  15. Rose PG , Bundy BN , Watkins EB , et al.   Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer . N Engl J Med . 1999;15:1144–1151
  16. Keys HM , Bundy BN , Stehman FB , et al.   Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma . N Engl J Med . 1999;15:1154–1161
  17. Eifel PJ , Winter K , Morris M , et al.   Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer (An update of Radiation Therapy Oncology Group (RTOG) study 90-01) . J Clin Oncol . 2004;22:872–880
  18. International Federation of Gynecology and Obstetrics, FIGO staging of gynecologic cancers (cervical and vulva) . Int J Gynecol Cancer . 1995;5:319–324
  19. Heller PB , Malfetano JH , Bunndy BN , et al.   Clinical-pathologic study of stage II, III, and IVA carcinoma of the cervix (Extended diagnostic evaluation for para-aortic node metastasis –a Gynecologic Oncology Group study) . Gynecol Oncol . 1990;38:425–430
  20. Stehman FB , Bundy BN , DiSaia PJ , et al.   Carcinoma of the cervix treated with radiation therapy I (A multivariate analysis of prognostic variables in the Gynecologic Oncology Group) . Cancer . 1991;67:2776–2785
  21. Burke TW , Hoskins WJ , Heller PB , et al.   Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma . Obstet Gynecol . 1987;69:382–385
  22. Wang CJ , Lai CH , Huang HJ , et al.   Recurrent cervical carcinoma after primary radical surgery . Am J Obstet Gynecol . 1999;181:518–524
  23. Sakurai H , Mitsuhashi N , Takahashi M , et al.   Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone (Patterns of recurrence, latent periods, and prognosis) . Int J Radiat Oncol Biol Phys . 2001;50:1136–1144
  24. Eralp Y , Saip P , Sakar B , et al.   Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix . Int J Gynecol Cancer . 2002;13:497–504
  25. Sommers GM , Grigsby PW , Perez CA , et al.   Outcome of recurrent cervical carcinoma following definitive irradiation . Gynecol Oncol . 1989;35:150–155
  26. Hong JH , Tsai CS , Lai CH , et al.   Recurrent squamous cell carcinoma of cervix following definitive radiotherapy . Int J Radiat Oncol Biol Phys . 2004;60:249–257
  27. Anderson TM , McMahon JJ , Nwogu CE , et al.   Pulmonary resection in metastatic uterine and cervical malignancies . Gynecol Oncol . 2001;83:472–476
  28. Chou HH , Wang CC , Lai CH , et al.   Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma . Int J Radiat Oncol Biol Phys . 2001;51:442–448
  29. Shingleton HM , Soong SJ , Gelder MS , et al.   Clinical and histological factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix . Obstet Gynecol . 1989;73:1027–1034
  30. Miller B , Morris M , Rutledge F , et al.   Aborted exenteratice procedures in recurrent cervical cancer . Gynecol Oncol . 1993;50:94–99
  31. Rutledge S , Carey MS , Prichard H , et al.   Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation (Is exenteration always necessary?) . Gynecol Oncol . 1994;52:353–359
  32. Hockel M . Laterally extended endopelvic resection (Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic sidewall) . Gynecol Oncol . 2003;91:369–377
  33. Mayr NA , Magnotta VA , Ethrhardt JC , et al.   Usefulness of tumor volumetry by magnetic resonance imaging in assessing response to radiation therapy in carcinoma of the uterine cervix . Int J Radiat Oncol Biol Phys . 1996;35:915–924
  34. Hatano K , Sekiya Y , Araki H , et al.   Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging . Int J Radiat Oncol Biol Phys . 1999;45:639–644
  35. Rose PG , Adler LP , Rodriguez M , et al.   Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging (A surgicopathologic study) . J Clin Oncol . 1999;17:41–45
  36. Grigsby PW , Siegel BA , Dehdashti F . Lymph node staging by positron emission tomography in patients with carcinoma of the cervix . J Clin Oncol . 2001;19:3745–3749
  37. Tasi CS , Chang TC , Lai CH , et al.   A preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes shown on MRI/CT images . Int J Radiat Oncol Biol Phys . 2004;58:1506–1512
  38. Lin WC , Hung YC , Yeh LS , et al.   Usefulless of (18)F-Fluorodeoxyglucose positon emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings . Gynecol Oncol . 2003;89:73–76
  39. Reinhardt MJ , Ehritt-Braun C , Vogelgesang D , et al.   Metastatic lymph nodes in patients with cervical cancer (Detection with MR imaging and FDG PET) . Radiology . 2001;218:776–782
  40. Sugawara Y , Eishruch A , Kosuda S , et al.   Evaluation of FDG PET in patients with cervical cancer . J Nucl Med . 1999;40:1125–1131
  41. Williams AD , Cousins C , Soutter WP , et al.   Detection of pelvic lymph node metastases in gynecologic malignancy (A comparison of CT, MR imaging, and positron emission tomography) . AJR Am J Roentgenol . 2001;177:343–348
  42. Narayan K , Hicks RJ , Jobling T , et al.   A comparison of MRI and PET scanning in surgically staged locoregionally advanced cervical cancer (Potential impact on treatment) . Int J Gynecol Cancer . 2001;11:263–271
  43. Esajas MD , Duk JM , de Bruijn HW , et al.   Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer . J Clin Oncol . 2001;19:3960–3966
  44. Ohno T , Nakayama Y , Nakamoto S , et al.   Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix . Cancer . 2003;97:3114–3120
  45. Bolli JA , Doering DL , Bosscher JR , et al.   Squamous cell carcinoma antigen (Clinical utility in squamous cell carcinoma of the uterine cervix) . Gynecol Oncol . 1994;55:169–173
  46. Tabata T , Takeshim N , Tanaka N , et al.   Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma . Tumor Biol . 2000;21:375–380
  47. Havrilesky LJ , Wong TZ , Secord AA , et al.   The role of PET scanning in the detecting of recurrent cervical cancer . Gynecol Oncol . 2003;90:186–190
  48. Sun SS , Chen TC , Yen RF , et al.   Value of whole body 18F-fluoro-2-deoxyglusose positron emission tomography in the evaluation of recurrent cervical cancer . Anticancer Res . 2001;21:2957–2962
  49. Unger JB , Ivy JJ , Connor P , et al.   Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women . Gynecol Oncol . 2004;94:212–216
  50. Ryu SY , Kim MH , Choi SC , et al.   Detection of early recurrence with 18F-FDG PET in patients with cervical cancer . J Nucl Med . 2003;44:347–352
  51. Nakamoto Y , Eisbruch A , Achtyes ED , et al.   Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy . Gynecol Oncol . 2002;84:289–295
  52. Grigsby PW , Siegel BA , Dehdashti F , et al.   Posttherapy surveillance monitoring of cervical cancer by FDG-PET . Int J Radiat Oncol Biol Phys . 2003;55:907–913
  53. Grigsby PW , Singh AK , Siegel BA , et al.   Lymph node control in cervical cancer . Int J Radiat Oncol Biol Phys . 2004;59:706–712
  54. Chang TC , Law KS , Hong JH , et al.   Positron emission tomography for unexplained serum SCC-Ag elevation in cervical cancer patients—a phase II study . Cancer . 2004;101:164–171
  55. Lai CH , Huang KG , See LC , et al.   Restaging of recurrent cervical cancer with dual-phase positron emission tomography . Cancer . 2004;100:544–552
  56. Yen TC , See LC , Ma SY , et al.   Defining priority of utilizing 18F-fluoro-D-deoxyglucose positron emission tomography for recurrent cervical cancer . J Nucl Med . 2004;45:1632–1639
  57. Yoshida Y , Kurokawa T , Kawahara K , et al.   Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-Fluorodeoxyglucose positron emission tomography (Preliminary results in three patients) . Gynecol Oncol . 2004;95:597–602
  58. Dehdashti F , Grigsby PW , Mintun MA , et al.   Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM (Relationship to therapeutic response-a preliminary report) . Int J Radiat Oncol Biol Phys . 2003;55:1233–1238
  59. Ell PJ , von Sxhulthess GK . PET/CT (A new road map) . Eur J Nucl Med Mol Imaging . 2002;29:719–720
  60. Grisaru D , Almong B , Levine C , et al.   The diagnostic accruracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies . Gynecol Oncol . 2004;94:680–684
  61. Boyle P , Leon ME , Maisonneuve P , et al.   Cancer control in women. Update 2003 . Int J Gynecol Obstet . 2003;83(suppl):179–202
  62. Cannistra SA . Cancer of the ovary . N Engl J Med . 1993;329:1550–1559
  63. Mann WJ , Patsner B , Cohen H , et al.   Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma . J Natl Cancer Inst . 1988;80:208–209
  64. Dowdy SC , Constantinou CL , Hartmann LC . Long-term follow-up of women with ovarian cancer after positive second-look laparotomy . Gynecol Oncol . 2003;91:563–568
  65. Kim HJ , Kim JK , Cho KS . CT features of serous surface papillary carcinoma of the ovary . AJR Am J Roentgenol . 2004;183:1721–1724
  66. Qayyum A , Coakley FV , Westphalen AC , et al.   Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer . Gynecol Oncol . 2005;96:301–306
  67. Hubner KF , McDonald TW , Niethammer JG , et al.   Assessment of primary and metastatic ovarian cancer by Positron Emission Tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG) . Gynecol Oncol . 1993;51:197–204
  68. Grab D , Flock F , Stohr I , et al.   Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positive emission tomography . Gynecol Oncol . 2000;77:454–459
  69. Rieber A , Nussle K , Stohr  , et al.   Preoperative diagnosis of ovarian tumors with magnetic resonance imaging (Comparison with transvaginal sonography, positive emission tomography and histologic findings) . AJR Am J Roentgenol . 2001;177:123–129
  70. Fenchel S , Grab D , Nuessle K , et al.   Asymptomatic adnexal masses (Correlation of FDG PET and histopathologic findings) . Radiology . 2002;223:780–788
  71. Kawahara K , Yoshida Y , Kurokawa T , et al.   Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography . J Comput Assist Tomogr . 2004;28:505–516
  72. Lerman H , Metser U , Grisaru D , et al.   Normal and abnormal 18F-FDG endometrial and ovarian uptake pre- and postmenopausal patients (assessment by PET/CT) . J Nucl Med . 2004;45:266–271
  73. Sironi S , Messa C , Mangili G , et al.   Integrated FDG PET/CT in patients with persistent ovarian cancer (correlation with histologic findings) . Radiology . 2004;233:433–440
  74. Yoshida Y , Kurokawa T , Kawahara K , et al.   Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer . AJR Am J Roentgenol . 2004;182:227–233
  75. Kubik-Huch RA , Dorffler W , von Schulthess GK , et al.   Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma . Eur Radiol . 2000;10:761–767
  76. Drieskens O , Stroobants S , Gysen M , et al.   Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer . Gynecol Obstet Invest . 2003;55:130–134
  77. Brown RS , Risher SJ , Wahl RL . Autoradiographic evaluation of the intratumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma . J Nucl Med . 1993;34:75–82
  78. Minn H , Kangas L , Knutilla V , et al.   Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells . Res Exp Med . 1991;191:27–35
  79. Vergote I , de Wever I , Tjalma W , et al.   Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian cancer (A retrospective analysis of 285 patients) . Gynecol Oncol . 1998;71:431–436
  80. Baum RP , Przetak C . Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET) . Q J Nucl Med . 2001;45:257–268
  81. Niloff JM , Bast RC , Schaetzl EM , et al.   Predictive value of CA-125 antigen levels in second-look procedures for ovarian cancer . Am J Obstet Gynecol . 1985;151:981–986
  82. Rubin SC , Hoskins WJ , Hakes TB , et al.   Serum CA 125 levels and the surgical findings in patients undergoing secondary operations for epithelial ovarian cancer . Am J Obstet Gynecol . 1989;160:667–671
  83. Patsner B , Day TG . Predictive value of CA-125 levels in advanced ovarian cancer . Am J Obstet Gynecol . 1987;156:440–441
  84. Lavin PT , Knapp RC , Malkasian G , et al.   CA 125 for the monitoring of ovarian carcinoma during primary therapy . Obstet Gynecol . 1987;69:223–227
  85. Rose PG , Reuter K , Sirois J , et al.   The impact of CA-125 on the sensitivity of abdominal/pelvic CT scan before second look laparotomy in ovarian cancer . Int J Gynecol Cancer . 1996;6:213–218
  86. Kim S , Chung JK , Kang SB , et al.   [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma . Eur J Nucl Med Mol Imaging . 2004;31:196–201
  87. Niloff JM , Knapp RC , Lavin PT , et al.   The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer . Am J Obstet Gynecol . 1986;155:56–60
  88. Fleming LW . Playing the waiting game…the asymptomatic patients with recurent ovarian cancer detected only by rising Ca-125 level . Scot Med J . 2001;46:81–83
  89. Markman M , Webster K , Zanotti K , et al.   Use of tamoxifen in asymptomatic patients with recurrent small volume ovarian cancer . Gynecol Oncol . 2004;93:390–393
  90. Makhija S , Howden N , Edwards R , et al.   Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma (a retrospective review) . Gynecol Oncol . 2002;85:53–58
  91. Chang WC , Hung YC , Kao CH , et al.   Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker . Neoplasma . 2002;49:329–333
  92. Zimny M , Siggelkow W , Schroder W , et al.   2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer . Gynecol Oncol . 2001;83:310–315
  93. Yen RF , Sun SS , Shen YY , et al.   Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer . Anticancer Res . 2001;21:3691–3694
  94. Garcia Velloso MJ , Boan Garcia JF , Villar Luque LM , et al.   F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence (Comparison with CT scan and CA 125) . Rev Esp Med Nucl . 2003;22:217–223
  95. Wilder JL , Pavlik E , Straughn JM , et al.   Clinical implications of rising CA-125 within the normal range in patients with epithelial ovarian cancer (A preliminary investigation) . Gynecol Oncol . 2003;89:233–235
  96. Kurokawa T , Yoshida Y , Kawahara K , et al.   Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range . Ann Nucl Med . 2002;6:491–493
  97. Cho SM , Ha HK , Byun JY , et al.   Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer . AJR Am J Roentgenol . 2002;179:391–395
  98. Bristow RE , del Carmen MG , Pannu HK , et al.   Clinically occult recurrent ovarian cancer (patient selection for secondary cytoreductive surgery using combined PET/CT) . Gynecol Oncol . 2003;90:519–528
  99. Reinhardt MJ , Matthies A , Biersack HJ . PET-imaging in tumors of the reproductive tract . Q J Nucl Med . 2002;46:105–112
  100. Talbot JN , Grahek D , Kerrou K , et al.   (18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers . Gynecol Obstet Fertil . 2001;29:775–798
  101. Morrow CP , Bundy BN , Kurman RJ , et al.   Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium (A Gynecologic Oncology Group study) . Gynecol Oncol . 1991;40:55–65
  102. Aalders JG , Abeler V , Kolstad P . Recurrent adenocarcinoma of the endometrium (A clinical and histopathological study of 379 patients) . Gynecol Oncol . 1984;17:85–103
  103. Kao MS . Management of recurrent endometrial cancer . Chang Gung Med J . 2004;27:639–645
  104. Jeyarajah AR , Gallagher CJ , Blake PR , et al.   Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer . Gynecol Oncol . 1996;63:47–52
  105. Moore TD , Phillips PH , Nerenstone SR , et al.   Systemic treatment of advanced and recurrent endometrial carcinoma (current status and future directions) . J Clin Oncol . 1991;9:1071–1088
  106. Manfredi R , Mirk P , Maresca G , et al.   Local-regional staging of endometrial carcinoma (role of MR imaging in surgical planning) . Radiology . 2004;231:372–378
  107. Frei KA , Kinkel K , Bonel HM , et al.   Prediction of deep myometrial invasion in patients with endometrial cancer (clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis) . Radiology . 2000;216:444–449
  108. Duk JM , Aalders JG , Fleuren GJ , et al.   CA 125 (a useful marker in endometrial carcinoma) . Am J Obstet Gynecol . 1986;155:1097–1102
  109. Patsner B , Mann WJ . The value of preoperative serum CA 125 levels in patients with a pelvic mass . Am J Obstet Gynecol . 1988;159:873–876
  110. Dotters DJ . Preoperative CA 125 in endometrial cancer (Is it useful?) . Am J Obstet Gynecol . 2000;182:1328–1334
  111. Belhocine T , de Barsy C , Hustinx R , et al.   Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma . Eur J Nucl Med Mol Imaging . 2002;29:1132–1139
  112. Saga T , Higashi T , Ishimori T , et al.   Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer . Ann Nucl Med . 2003;17:197–203
  113. Nakahara T , Fujii H , Ide M , et al.   F-18 FDG uptake in endometrial cancer . Clin Nucl Med . 2001;26:82–83
  114. Lentz SS . Endometrial carcinoma diagnosed by positron emission tomography (a case report) . Gynecol Oncol . 2002;86:223–224
  115. Horowitz NS , Dehdashti F , Herzog TJ , et al.   Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer . GynecolOncol . 2004;101:164–171
  116. Podratz KC , Symmonds RE , Taylor WF . Carcinoma of the vulva (Analysis of treatment failures) . Am J Obstet Gynecol . 1982;143:340–347
  117. Heaps JM , Fu YS , Montz FJ , et al.   Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva . Gynecol Oncol . 1990;38:309–314
  118. Sedlis A , Homesley H , Bundy BN , et al.   Positive groin lymph nodes in superficial squamous cell vulvar cancer . Am J Obstet Gynecol . 1987;156:1159–1164
  119. Hopkins MP , Reid GC , Morley GW . The surgical management of recurrent squamous cell carcinoma of the vulva . Obstet Gynecol . 1990;75:1001–1005
  120. Piura B , Masotina A , Murdoch J , et al.   Recurrent squamous cell carcinoma of the vulva (A study of 73 cases) . Gynecol Oncol . 1993;48:189–195
  121. Chakalova G , Karagiozov A . The surgical management of recurrent carcinoma of the vulva . Eur J Gynecol Oncol . 1993;14:318–322
  122. Hruby G , MacLeod C , Firth I . Radiation treatment in recurrent squamous cell cancer of the vulva . Int J Radiat Oncol Biol Phys . 2000;46:1193–1197
  123. Tewari K , Cappuccini F , Syed AM , et al.   Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer . Am J Obstet Gynecol . 1999;181:91–98
  124. Cohn DE , Dehdashti F , Gibb RK , et al.   Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer . Gynecol Oncol . 2002;85:179–184
  125. Bower M , Newlands ES , Holden L , et al.   EMA/CO for high-risk gestational trophoblastic tumours (results from a cohort of 272 patients) . J Clin Oncol . 1997;15:2636–2643
  126. Lehman E , Gershenson DM , Burke TW , et al.   Salvage surgery for chemorefractory gestational trophoblastic disease . J Clin Oncol . 1994;12:2737–2742
  127. Newlands ES , Bower M , Holden L , et al.   Management of resistant gestational trophoblastic tumours . J Reprod Med . 1998;43:111–118
  128. Feltmate CM , Genest DR , Wise L , et al.   Placental site trophoblastic tumour (A 17-year experience at the New England Trophoblastic Disease Center) . Gynecol Oncol . 2001;82:415–419
  129. World Health Organization . Gestational trophoblastic diseases . In: WHO Technical Report Series . Switzerland: WHO; 1983;p. 692
  130. Bagshawe KD . Choriocarcinoma. A model for tumour markers . Acta Oncol . 1992;31:99–106
  131. Hebart H , Erley C , Kaskas B , et al.   Positron emission tomography helps to diagnose tumour emboli and residual disease in choriocarcinoma . Ann Oncol . 1996;7:416–418
  132. Truenbach J , Pereira PL , Huppert PE , et al.   Primary choriocarcinoma of the pulmonary artery mimicking pulmonary embolism . Br J Radiol . 1997;70:843–845
  133. Zhuang H , Yamamoto AJ , Ghesani N , et al.   Detection of choriocarcinoma in the lung by FDG positron emission tomography . Clin Nucl Med . 2001;26:723
  134. Dose J , Bohuslavizki K , Huneke B , et al.   Detection of intramural choriocarcinoma of the uterus with 18F-FDG-PET. A case report . Clin Positron Imaging . 2000;3:37–40
  135. Sironi S , Picchio M , Mangili G , et al.   [18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumour (Preliminary results in three patients) . Gynecol Oncol . 2003;91:226–230
  136. Chang TC, Yen TC, Ma SY, et al: 18F-fluoro-D-deoxyglucose positron emission tomography of trophoblastic tumor: A pilot study. Eur J Nucl Med Mol Imaging (in press)

 Supported by grants from the National Science Council-Taiwan (NSC 92-2314-B-182A-039; NSC 92-2314-B-182A-004) and the Chang Gung Memorial Hospital (CTRP-016, -018, and -020).

PII: S0001-2998(05)00051-6

doi: 10.1053/j.semnuclmed.2005.08.004

Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 93-104 , January 2006

Article Tools

* Image Usage & Resolution